CUMULATIVE
SUPPLEMENT 4
APRIL 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

1.1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 4
APRIL 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
	10360	10372		
DRUG PRODUCTS LISTED	2682 (25.9%)	2696 (26.0%)		
SINGLE SOURCE	7568 (73.1%)	7566 (72.9%)		
MULTISOURCE	7257 (70.0%)	7263 (70.0%)		
THERAPEUTICALLY EQUIVALENT				
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	303 (2.9%)		
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)		
NEW MOLECULAR ENTITIES APPROVED	2	6		
NUMBER OF APPLICANTS	594	582		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

Please Note

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product throuth the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
CTNA	Change. Trade Name.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

TRIAPRIN

@ DUNHALL — 325MG;50MG — N89268 001 JUL 02, 1987 FEB WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

@ ROBERTS AND HAUCK — 325MG;50MG;40MG — N87628 001 OCT 01, 1986 FEB WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

AB WEST WARD — 325MG;50MG;40MG;30MG — N75618 001 MAR 23, 2001 MAR NEWA

FIORICET W/ CODEINE

AB + NOVARTIS — 325MG;50MG;40MG;30MG — N20232 001 JUL 30, 1992 MAR CFTG

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

+ MIKART — 712.8MG;60MG;32MG — N40316 001 APR 28, 1999 JAN CTNA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

CAPITAL WITH CODEINE

@ CARNRICK — 325MG;30MG — N83643 001 MAY 31, 1974 FEB WDRP

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A> + WATSON LABS — 750MG;10MG — N40094 004 MAR 22, 1999 APR NEWA

LORTAB

AA + WATSON LABS — 325MG;5MG — N40099.001 JUN 25, 1997 JAN CAHN

NORCO

>A> AA WATSON LABS — 325MG;7.5MG — N40148 003 SEP 12, 2000 APR NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB MALLINCKRODT — 650MG;100MG — N75738 001 FEB 02, 2001 FEB NEWA

AB VINTAGE PHARMS — 325MG;50MG — N74843 002 FEB 15, 2001 FEB NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

AP GENSIA SICOR PHARMS — EQ 50MG BASE/ML — N75627 001 MAR 28, 2001 MAR NEWA

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

>A> VENTOLIN HFA

>A> + GLAXO — EQ 0.09MG BASE/INH — N20983 001 APR 19, 2001 APR NEWA

		ALBUTEROL SULFATE					
		SOLUTION; INHALATION					
>A>		ACCUNEB					
>A>	+	DEY	EQ 0.021% BASE	N20949	002	APR 30, 2001	APR NEWA
>A>	+		EQ 0.042% BASE	N20949	001	APR 30, 2001	APR NEWA
		ALBUTEROL SULFATE					
	AN	ROXANE	EQ 0.083% BASE	N75129	001	FEB 13, 2001	FEB NEWA
		ALBUTEROL SULFATE; IPRATROPIUM BROMIDE					
		SOLUTION; INHALATION					
		DUONEB					
	+	DEY	EQ 0.083% BASE;0.017% BASE	N20950	001	MAR 21, 2001	MAR NEWA
		AMIKACIN SULFATE					
		INJECTABLE; INJECTION					
		AMIKACIN SULFATE					
>D>	AP	ABBOTT	EQ 250MG BASE/ML	N63265	001	NOV 30, 1994	APR DISC
>D>	AP		EQ 250MG BASE/ML	N63266	001	OCT 31, 1994	APR DISC
>A>		@	EQ 250MG BASE/ML	N63265	001	NOV 30, 1994	APR DISC
>A>		@	EQ 250MG BASE/ML	N63266	001	OCT 31, 1994	APR DISC
>D>	AP	ELKINS SINN	EQ 250MG BASE/ML	N63275	001	MAY 18, 1992	APR DISC
>A>		@	EQ 250MG BASE/ML	N63275	001	MAY 18, 1992	APR DISC
		AMIODARONE HYDROCHLORIDE					
		TABLET; ORAL					
		AMIODARONE HCL					
	AB	BARR	200MG	N75389	001	JAN 25, 2001	JAN NEWA
	AB	TARO	200MG	N75424	001	MAR 30, 2001	MAR NEWA
		AMOXICILLIN					
		CAPSULE; ORAL					
		AMOXICILLIN					
		@ LABS ATRAL	250MG	N62528	001	AUG 07, 1985	FEB WDRP
		@	500MG	N62528	002	AUG 07, 1985	FEB WDRP
>D>	AB	MYLAN	250MG	N62067	001	AUG 14, 1980	APR DISC
>D>	AB		500MG	N62067	002	AUG 14, 1980	APR DISC
>A>		@	250MG	N62067	001	AUG 14, 1980	APR DISC
>A>		@	500MG	N62067	002	AUG 14, 1980	APR DISC
>D>	AB	TEVA	250MG	N63030	001	FEB 28, 1989	APR DISC
>D>	AB		500MG	N63031	001	FEB 28, 1989	APR DISC
>A>		@	250MG	N63030	001	FEB 28, 1989	APR DISC
>A>		@	500MG	N63031	001	FEB 28, 1989	APR DISC
		TRIMOX					
>D>	AB	APOTHECON	250MG	N63099	001	MAR 20, 1992	APR DISC
>D>	AB		500MG	N63099	002	MAR 20, 1992	APR DISC
>A>		@	250MG	N63099	001	MAR 20, 1992	APR DISC
>A>		@	500MG	N63099	002	MAR 20, 1992	APR DISC
>D>		WYMOX					
>D>	AB	WYETH AYERST	250MG	N62120	001	APR 28, 1978	APR DISC
>D>	AB		500MG	N62120	002	APR 28, 1978	APR DISC
>A>		@	250MG	N62120	001	APR 28, 1978	APR DISC
>A>		@	500MG	N62120	002	APR 28, 1978	APR DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 7.5

>D>	+	SHIRE	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CTEC
>A>			1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CTEC

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN
+		100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	AP	HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC
>D>	AP		EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC
>D>	AP		EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC
>D>	AP		EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC
>D>	AP		EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC
>D>	AP		EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC
>D>	AP		EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC
>D>	AP		EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC
>A>		@	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC
>A>		@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC
>A>		@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC
>A>		@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC
>A>		@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC
>A>		@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC
>A>		@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC
>A>		@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

TOTACILLIN

@	SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
@		EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

@	GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/V				

			IAL;0.14MG/VIAL;17MG/VIAL; 1MG/VIAL;1.4MG/VIAL;1.2MG/ VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA
		ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E					
		FOR SOLUTION; IV (INFUSION)					
		M.V.I. PEDIATRIC					
	+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.00 1MG/VIAL;5MG/VIAL;0.01MG/ VIAL;0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;1MG/VIAL;1.4MG/ VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/ VIAL	N18920 001	SEP 21, 2000	FEB	NEWA
		ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE					
		TABLET; ORAL					
		INVAGESIC					
	AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN
		INVAGESIC FORTE					
	AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN
		ATORVASTATIN CALCIUM					
		TABLET; ORAL					
		LIPITOR					
		PFIZER	EQ 10MG BASE	N20702 001	DEC 17, 1996	MAR	CAHN
			EQ 20MG BASE	N20702 002	DEC 17, 1996	MAR	CAHN
			EQ 40MG BASE	N20702 003	DEC 17, 1996	MAR	CAHN
	+		EQ 80MG BASE	N20702 004	APR 07, 2000	MAR	CAHN
		ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE					
		TABLET; ORAL					
		DIPHENOXYLATE HCL AND ATROPINE SULFATE					
		@ INWOOD LABS	0.025MG;2.5MG	N85509 001	MAR 09, 1978	FEB	WDRP
		BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE					
		OINTMENT; OPHTHALMIC					
		NEO-POLYCIN					
		@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP
		BETAMETHASONE DIPROPIONATE					
		CREAM; TOPICAL					
		BETAMETHASONE DIPROPIONATE					
>D>	AB	CLAY PARK	EQ 0.05% BASE	N74579 001	NOV 26, 1997	APR	DISC
>A>		@	EQ 0.05% BASE	N74579 001	NOV 26, 1997	APR	DISC
		BETAXOLOL HYDROCHLORIDE					
		SOLUTION/DROPS; OPHTHALMIC					
		BETAXOLOL HCL					
>A>	AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA

BIMATOPROST
SOLUTION/DROPS; OPHTHALMIC
LUMIGAN
\+ ALLERGAN 0.03% N21275 001 MAR 16, 2001 MAR NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
AB TEVA 2.5MG;6.25MG N75686 001 JAN 19, 2001 JAN NEWA
AB 5MG;6.25MG N75686 002 JAN 19, 2001 JAN NEWA
AB 10MG;6.25MG N75686 003 JAN 19, 2001 JAN NEWA

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN
>D> + ALLERGAN 0.5% N20490 001 MAR 13, 1997 APR DISC
>A> @ 0.5% N20490 001 MAR 13, 1997 APR DISC
ALPHAGAN P
\+ ALLERGAN 0.15% N21262 001 MAR 16, 2001 MAR NEWA

BUPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR
>D> + GLAXO WELLCOME 50MG N20358 001 OCT 04, 1996 APR CTEC
>A> 50MG N20358 001 OCT 04, 1996 APR CTEC
>D> + 100MG N20358 002 OCT 04, 1996 APR CTEC
>A> 100MG N20358 002 OCT 04, 1996 APR CTEC

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPAR
AB BRISTOL MYERS SQUIBB 5MG N18731 001 SEP 29, 1986 MAR CFTG
AB 10MG N18731 002 SEP 29, 1986 MAR CFTG
AB 15MG N18731 003 APR 22, 1996 MAR NEWA
BUSPIRONE HCL
AB DANBURY PHARMA 5MG N74253 001 MAR 28, 2001 MAR NEWA
AB 10MG N74253 002 MAR 28, 2001 MAR NEWA
AB MYLAN 15MG N75272 003 MAR 28, 2001 MAR NEWA
AB PAR PHARM 7.5MG N75467 002 MAR 28, 2001 MAR NEWA

CALCIUM ACETATE
CAPSULE; ORAL
>A> PHOSLO
>A> BRAINTREE EQ 84.5MG CALCIUM N21160 001 APR 02, 2001 APR NEWA
>A> + EQ 169MG CALCIUM N21160 002 APR 02, 2001 APR NEWA

CAPTOPRIL
TABLET; ORAL
CAPTOPRIL
AB GENEVA PHARMS TECH 12.5MG N74481 001 FEB 13, 1996 JAN CAHN
AB 25MG N74481 002 FEB 13, 1996 JAN CAHN
AB 50MG N74481 003 FEB 13, 1996 JAN CAHN

			100MG	N74481 004	FEB 13, 1996	JAN	CAHN
AB							
	CARBACHOL						
	SOLUTION; INTRAOCULAR						
	CARBASTAT						
AT	NOVARTIS		0.01%	N73677 001	APR 28, 1995	FEB	CAHN
	CARBIDOPA; LEVODOPA						
	TABLET; ORAL						
	CARBIDOPA AND LEVODOPA						
	@ SCS		10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
	@		25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
	@		25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP
	CASPOFUNGIN ACETATE						
	INJECTABLE; IV (INFUSION)						
	CANCIDAS						
+	MERCK RES		50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
+			70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA
	CEFACLOR						
	TABLET, EXTENDED RELEASE; ORAL						
	CECLOR CD						
AB +	LILLY		EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG
>D> +			EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC
>A>			EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC
	CEFACLOR						
AB	ZENITH GOLDLINE		EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA
	CEFAZOLIN SODIUM						
	INJECTABLE; INJECTION						
	CEFAZOLIN SODIUM						
>D> AP	TEVA		EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989	APR	DISC
>D> AP			EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989	APR	DISC
>D> AP			EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989	APR	DISC
>A>	@		EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989	APR	DISC
>A>	@		EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989	APR	DISC
>A>	@		EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989	APR	DISC
	CEFONICID SODIUM						
	INJECTABLE; INJECTION						
	MONOCID						
>D>	SMITHKLINE BEECHAM		EQ 1GM BASE/VIAL	N63295 001	JUL 26, 1993	APR	DISC
>A>	@		EQ 1GM BASE/VIAL	N63295 001	JUL 26, 1993	APR	DISC
	CEFTAZIDIME						
	INJECTABLE; INJECTION						
	TAZICEF						
AP	ABBOTT		500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN
AP			1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN
AP			1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN
AP			2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN
AP			2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN

>D>
>D>
>D>
>A>
>A>

AP			6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN

CEFUROXIME SODIUM
INJECTABLE; INJECTION
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

+	B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA
+		EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA

CEPHALOTHIN SODIUM
INJECTABLE; INJECTION
KEFLIN IN PLASTIC CONTAINER

>D>			EQ 1GM BASE/VIAL	N62549 001	SEP 10, 1985	APR	DISC
>D>	AP +	LILLY	EQ 2GM BASE/VIAL	N62549 002	SEP 10, 1985	APR	DISC
>D>	AP +		EQ 1GM BASE/VIAL	N62549 001	SEP 10, 1985	APR	DISC
>A>		@	EQ 2GM BASE/VIAL	N62549 002	SEP 10, 1985	APR	DISC
>A>		@					

CHLORAMPHENICOL
SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL

		@ AKORN	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP

CHLORDIAZEPOXIDE HYDROCHLORIDE
CAPSULE; ORAL
CHLORDIAZACHEL

		@ RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
		@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
		@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP

CHLORDIAZEPOXIDE HCL

		@ FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
		@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
		@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP

CHLORPHENIRAMINE MALEATE
TABLET; ORAL
CHLORPHENIRAMINE MALEATE

		@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
		@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP

CIMETIDINE
TABLET; ORAL
CIMETIDINE

AB		GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
AB			300MG	N74506 002	JAN 24, 1996	JAN	CAHN
AB			400MG	N74506 003	JAN 24, 1996	JAN	CAHN
AB			800MG	N74506 004	JAN 24, 1996	JAN	CAHN

CLINDAMYCIN HYDROCHLORIDE
CAPSULE; ORAL
CLEOCIN HCL

AB	+	PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG

CLINDAMYCIN HCL

AB		RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
AB			EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA

CLINDAMYCIN PHOSPHATE
INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

>D>	AP	GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
>D>	AP		EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
>A>		@	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
>A>		@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC

CLOBETASOL PROPIONATE
CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB1	STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA

CLONAZEPAM
TABLET; ORAL
CLONAZEPAM

>A>	AB	CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
>A>	AB		1MG	N75423 002	APR 27, 2001	APR	NEWA
>A>	AB		2MG	N75423 003	APR 27, 2001	APR	NEWA

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

		@ ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
		@	7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
		@	15MG	N71779 001	JUL 14, 1987	JAN	DISC

CROMOLYN SODIUM
SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET; ORAL

		ORETICYL 25					
		@ ABBOTT	0.125MG;25MG	N12148 001	DEC 14, 1959	MAR	DISC
		ORETICYL 50					
		@ ABBOTT	0.125MG;50MG	N12148 003	DEC 14, 1959	MAR	DISC
		ORETICYL FORTE					
		@ ABBOTT	0.25MG;25MG	N12148 002	DEC 14, 1959	MAR	DISC

DESONIDE
OINTMENT; TOPICAL
DESONIDE

AB	ALTANA	0.05%	N75751 001	MAR 12, 2001	MAR	NEWA

DEXAMETHASONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

		@ DELL LABS	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP
		SOLUTION/DROPS; OTIC					
		@ AKORN	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN

SUSPENSION/DROPS; OPHTHALMIC

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544 001	OCT 29, 1984	FEB	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	BARR	5MG	N40361 001	JAN 31, 2001	JAN	NEWA
AA		10MG	N40361 002	JAN 31, 2001	JAN	NEWA

DEXTROSTAT

AA	+ SHIRE RICHWOOD	10MG	N84051 002	MAY 29, 1975	JAN	CFTG

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB	EON	50MG	N75582 001	FEB 23, 2001	FEB	NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

	+ BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000	MAR	CAHN

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

>D>	AB SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC
>D>	AB	EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC
>D>	AB	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC
>A>	@	EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC
>A>	@					

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002	MAR 18, 2098	MAR	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

	@ NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP
	@	50MG	N86544 001	FEB 08, 1979	FEB	WDRP

DISULFIRAM

TABLET; ORAL

ANTABUSE

	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	JAN	CAHN
		500MG	N88483 001	DEC 08, 1983	JAN	CAHN
	+					
	@ SIDMAK LABS	250MG	N07883 003	NOV 03, 1970	MAR	CAHN

		@	500MG	N07883 002	JUN 01, 1953	MAR	CAHN
		DOXAZOSIN MESYLATE					
		TABLET; ORAL					
		DOXAZOSIN MESYLATE					
	AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
	AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
	AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
	AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA
		DOXYCYCLINE					
		FOR SUSPENSION; ORAL					
		DOXYCHEL					
		@ RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP
		VIBRAMYCIN					
	+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC
		DOXYCYCLINE HYCLATE					
		CAPSULE; ORAL					
>D>		DOXY-LEMMON					
>D>	AB	TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
>D>	AB		EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC
>A>		@	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
>A>		@	EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC
		DOXYCYCLINE HYCLATE					
>D>	AB	CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
>D>	AB		EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
>A>		@	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
>A>		@	EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
>D>	AB	HALSEY	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC
>D>	AB		EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC
>A>		@	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC
>A>		@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC
		INJECTABLE; INJECTION					
		DOXYCHEL HYCLATE					
		@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP
		DOXYCYCLINE					
>D>	AP	ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC
>D>	AP		EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC
>A>		@	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC
>A>		@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC
		TABLET; ORAL					
		DOXYCYCLINE HYCLATE					
>D>	AB	HALSEY	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC
>A>		@	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC
		PERIOSTAT					
	+	COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001	FEB	NEWA
		ENALAPRIL MALEATE					
		TABLET; ORAL					
		ENALAPRIL MALEATE					
	AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN	NEWA
	AB		5MG	N75657 002	JAN 23, 2001	JAN	NEWA

	AB		10MG	N75657 003	JAN 23, 2001	JAN	NEWA
	AB		20MG	N75657 004	JAN 23, 2001	JAN	NEWA
	AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR	NEWA
	AB		5MG	N75178 001	MAR 23, 2001	MAR	NEWA
	AB		10MG	N75178 003	MAR 23, 2001	MAR	NEWA
	AB		20MG	N75178 004	MAR 23, 2001	MAR	NEWA
	ENFLURANE						
	LIQUID; INHALATION						
	ENFLURANE						
	AN	MINRAD	99.9%	N74396 001	JUL 29, 1994	FEB	CAHN
	ENOXAPARIN SODIUM						
	INJECTABLE; SUBCUTANEOUS						
	LOVENOX						
>A>	+	AVENTIS	30MG/0.3ML	N20164 001	MAR 29, 1993	APR	CAHN
>A>	+		40MG/0.4ML	N20164 002	JAN 30, 1998	APR	CAHN
>A>	+		60MG/0.6ML	N20164 003	MAR 27, 1998	APR	CAHN
>A>	+		80MG/0.8ML	N20164 004	MAR 27, 1998	APR	CAHN
>A>	+		90MG/0.6ML	N20164 006	JUN 02, 2000	APR	CAHN
>A>	+		100MG/ML	N20164 005	MAR 27, 1998	APR	CAHN
>A>	+		120MG/0.8ML	N20164 007	JUN 02, 2000	APR	CAHN
>A>	+		150MG/ML	N20164 008	JUN 02, 2000	APR	CAHN
>D>	+	AVENTIS PHARMS	30MG/0.3ML	N20164 001	MAR 29, 1993	APR	CAHN
>D>	+		40MG/0.4ML	N20164 002	JAN 30, 1998	APR	CAHN
>D>	+		60MG/0.6ML	N20164 003	MAR 27, 1998	APR	CAHN
>D>	+		80MG/0.8ML	N20164 004	MAR 27, 1998	APR	CAHN
>D>	+		100MG/ML	N20164 005	MAR 27, 1998	APR	CAHN
>D>	+		90MG/0.6ML	N20164 006	JUN 02, 2000	APR	CAHN
>D>	+		120MG/0.8ML	N20164 007	JUN 02, 2000	APR	CAHN
>D>	+		150MG/ML	N20164 008	JUN 02, 2000	APR	CAHN
	EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	DURANEST						
>D>	+	ASTRAZENECA	0.005MG/ML;1%	N17751 006	AUG 30, 1976	APR	CAHN
>D>	+		0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	APR	CAHN
>A>	+	DENTSPLY PHARM	0.005MG/ML;1%	N17751 006	AUG 30, 1976	APR	CAHN
>A>	+		0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	APR	CAHN
	EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
>D>	@	ASTRAZENECA	0.005MG/ML;0.5%	N17751 004	AUG 30, 1976	APR	CAHN
>A>	@	DENTSPLY PHARM	0.005MG/ML;0.5%	N17751 004	AUG 30, 1976	APR	CAHN
	EPINEPHRINE; LIDOCAINE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	LIDOCATON						
	@	PHARMATON	0.02MG/ML;2%	N84728 001	AUG 17, 1983	FEB	WDRP

ERGOCALCIFEROL
CAPSULE; ORAL
VITAMIN D

		@ IMPAX LABS	50,000 IU	N80951	001	JUL 13, 1973	FEB	DISC

ERYTHROMYCIN
SOLUTION; TOPICAL
ERYTHROMYCIN

>D>	AT	CLAY PARK	2%	N63038	001	JAN 11, 1991	APR	DISC
>A>		@	2%	N63038	001	JAN 11, 1991	APR	DISC

TABLET, DELAYED RELEASE; ORAL
E-BASE

>D>	AB	BARR	333MG	N63028	001	MAY 15, 1990	APR	DISC
>A>		@	333MG	N63028	001	MAY 15, 1990	APR	DISC

ERYTHROMYCIN ESTOLATE
CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE

>D>	AB	DANBURY PHARMA	EQ 250MG BASE	N62087	001	JUN 14, 1979	APR	DISC
>A>		@	EQ 250MG BASE	N62087	001	JUN 14, 1979	APR	DISC

>D> SUSPENSION/DROPS; ORAL
>D> ILOSONE

>D>	+	LILLY	EQ 100MG BASE/ML	N61894	003	JAN 07, 1975	APR	DISC
>A>		@	EQ 100MG BASE/ML	N61894	003	JAN 07, 1975	APR	DISC

>D> TABLET; ORAL
>D> ILOSONE

>D>	+	LILLY	EQ 500MG BASE	N61896	001	JAN 03, 1975	APR	DISC
>A>		@	EQ 500MG BASE	N61896	001	JAN 03, 1975	APR	DISC

ERYTHROMYCIN STEARATE
TABLET; ORAL
>D> WYAMYCIN S

>D>	AB	WYETH AYERST	EQ 250MG BASE	N61675	001	OCT 06, 1972	APR	DISC
>D>	AB		EQ 500MG BASE	N61675	002	JUL 13, 1973	APR	DISC
>A>		@	EQ 250MG BASE	N61675	001	OCT 06, 1972	APR	DISC
>A>		@	EQ 500MG BASE	N61675	002	JUL 13, 1973	APR	DISC

ESOMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED REL PELLETS; ORAL
NEXIUM

	+	ASTRAZENECA	EQ 20MG BASE	N21153	001	FEB 20, 2001	FEB	NEWA
	+		EQ 40MG BASE	N21153	002	FEB 20, 2001	FEB	NEWA

ESTRADIOL; NORETHINDRONE ACETATE
FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

		NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870	001	AUG 07, 1998	MAR	CAHN
	+		0.05MG/24HR;0.25MG/24HR	N20870	002	AUG 07, 1998	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET; ORAL-28
PREMPRO

	+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5M

				G	N20527 001	NOV 17, 1995	JAN	CTNA
		+		0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	JAN	CTNA
			PREMPRO (PREMARIN;CYCRIN)					
		+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5M				
				G	N20303 001	DEC 30, 1994	JAN	CTNA
			ESTROPIPATE					
			TABLET; ORAL					
			ORTHO-EST					
	AB		WOMEN FIRST HLTHCARE	0.75MG	N89567 001	FEB 27, 1991	JAN	CAHN
	AB			1.5MG	N89582 001	JUL 17, 1991	JAN	CAHN
			ETHINYL ESTRADIOL; LEVONORGESTREL					
			TABLET; ORAL-21					
>A>			ALESSE					
>A>	AB	+	WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997	APR	CTEC
>D>	BX	+		0.02MG;0.1MG	N20683 001	MAR 27, 1997	APR	CTEC
>A>			AVIANE-21					
>A>	AB		DURAMED	0.02MG;0.1MG	N75796 002	APR 30, 2001	APR	NEWA
			TABLET; ORAL-28					
>A>			ALESSE					
>A>	AB		WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997	APR	CTEC
>D>	BX			0.02MG;0.1MG	N20683 002	MAR 27, 1997	APR	CTEC
>A>			AVIANE-28					
>A>	AB		DURAMED	0.02MG;0.1MG	N75796 001	APR 30, 2001	APR	NEWA
			ETHINYL ESTRADIOL; NORETHINDRONE ACETATE					
			TABLET; ORAL-28					
			LOESTRIN FE 1.5/30					
	AB	+	PARKE DAVIS	0.03MG;1.5MG	N17355 001	APR 30, 1973	FEB	CFTG
			LOESTRIN FE 1/20					
	AB	+	PARKE DAVIS	0.02MG;1MG	N17354 001	APR 30, 1973	FEB	CFTG
			MICROGESTIN FE 1.5/30					
	AB		WATSON LABS	0.03MG;1.5MG	N75548 001	FEB 05, 2001	FEB	NEWA
			MICROGESTIN FE 1/20					
	AB		WATSON LABS	0.02MG;1MG	N75647 001	FEB 05, 2001	FEB	NEWA
			ETHOSUXIMIDE					
			SYRUP; ORAL					
			ZARONTIN					
	AA	+	PARKE DAVIS	250MG/5ML	N80258 001	FEB 13, 1974	JAN	CRLD
			ETIDOCAINE HYDROCHLORIDE					
			INJECTABLE; INJECTION					
			DURANEST					
>D>			@ ASTRAZENECA	0.5%	N17751 003	AUG 30, 1976	APR	CAHN
>D>		+		1%	N17751 005	AUG 30, 1976	APR	CAHN
>A>			@ DENTSPLY PHARM	0.5%	N17751 003	AUG 30, 1976	APR	CAHN
>A>		+		1%	N17751 005	AUG 30, 1976	APR	CAHN
			ETODOLAC					
			TABLET, EXTENDED RELEASE; ORAL					
			ETODOLAC					
	AB		TEVA	400MG	N75665 003	FEB 05, 2001	FEB	NEWA

			FAMCICLOVIR					
			TABLET; ORAL					
			FAMVIR					
			NOVARTIS	125MG	N20363 003	DEC 11, 1995	JAN	CAHN
				250MG	N20363 001	APR 26, 1996	JAN	CAHN
		+		500MG	N20363 002	JUN 29, 1994	JAN	CAHN
			FAMOTIDINE					
			INJECTABLE; INJECTION					
>A>			FAMOTIDINE					
>A>	AP		AM PHARM PARTNERS	10MG/ML	N75709 001	APR 16, 2001	APR	NEWA
>A>	AP		APOTHECON	10MG/ML	N75707 001	APR 16, 2001	APR	NEWA
>A>	AP		BEDFORD	10MG/ML	N75651 001	APR 16, 2001	APR	NEWA
>A>	AP			10MG/ML	N75684 001	APR 16, 2001	APR	NEWA
>A>	AP		ESI LEDERLE	10MG/ML	N75488 001	APR 16, 2001	APR	NEWA
>A>	AP		FAULDING	10MG/ML	N75705 001	APR 16, 2001	APR	NEWA
>A>			FAMOTIDINE PRESERVATIVE FREE					
>A>	AP		AM PHARM PARTNERS	10MG/ML	N75813 001	APR 16, 2001	APR	NEWA
>A>	AP		APOTHECON	10MG/ML	N75708 001	APR 16, 2001	APR	NEWA
>A>	AP		BEDFORD	10MG/ML	N75622 001	APR 16, 2001	APR	NEWA
>A>	AP		BEN VENUE	10MG/ML	N75825 001	APR 17, 2001	APR	NEWA
>A>	AP		ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001	APR	NEWA
>A>	AP		FAULDING	10MG/ML	N75669 001	APR 16, 2001	APR	NEWA
>A>			PEPCID					
>A>	AP	+	MERCK	10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG
>D>		+		10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG
>A>			PEPCID PRESERVATIVE FREE					
>A>	AP	+	MERCK	10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG
>D>		+		10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG
			TABLET; ORAL					
>A>			FAMOTIDINE					
>A>	AB		CARLSBAD	20MG	N75805 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75805 002	APR 16, 2001	APR	NEWA
>A>	AB		DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75062 001	APR 16, 2001	APR	NEWA
>A>	AB		DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75718 002	APR 16, 2001	APR	NEWA
>A>	AB		EON	20MG	N75793 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75793 002	APR 16, 2001	APR	NEWA
>A>	AB		GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75302 002	APR 16, 2001	APR	NEWA
>A>	AB		GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA
>A>	AB			40MG	N75457 002	APR 18, 2001	APR	NEWA
>A>	AB		MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75704 002	APR 16, 2001	APR	NEWA
>A>	AB		TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75311 002	APR 16, 2001	APR	NEWA
>A>	AB		WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75786 002	APR 16, 2001	APR	NEWA
>A>	AB		ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
>A>	AB			40MG	N75511 002	APR 16, 2001	APR	NEWA
>A>			PEPCID					

FAMOTIDINE
TABLET; ORAL
PEPCID

>A>	AB		MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
>A>	AB	+		40MG	N19462 002	OCT 15, 1986	APR	CFTG
>D>				20MG	N19462 001	OCT 15, 1986	APR	CFTG
>D>		+		40MG	N19462 002	OCT 15, 1986	APR	CFTG

FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE PRESERVATIVE FREE

		@	MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

	AP		AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001	FEB	NEWA

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

>D>	AT		CLAY PARK	0.01%	N86810 001	MAR 04, 1982	APR	DISC
>D>	AT			0.025%	N86811 001	MAR 04, 1982	APR	DISC
>A>		@		0.01%	N86810 001	MAR 04, 1982	APR	DISC
>A>		@		0.025%	N86811 001	MAR 04, 1982	APR	DISC

FLUOROMETHOLONE
SUSPENSION; OPHTHALMIC
FLUOR-OP

	AB		NOVARTIS	0.1%	N70185 001	FEB 27, 1986	FEB	CAHN

FLUOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS; ORAL
PROZAC WEEKLY

		+	LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001	FEB	NEWA

FLURBIPROFEN
TABLET; ORAL
FLURBIPROFEN

>A>	AB		CARACO	50MG	N75058 001	APR 27, 2001	APR	NEWA
>A>	AB			100MG	N75058 002	APR 27, 2001	APR	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

	AB		BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA
	AB			50MG	N75897 002	JAN 25, 2001	JAN	NEWA
	AB			100MG	N75897 003	JAN 25, 2001	JAN	NEWA
	AB		INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
	AB			50MG	N75887 002	JAN 05, 2001	JAN	NEWA
	AB			100MG	N75887 003	JAN 05, 2001	JAN	NEWA
	AB		SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
	AB			50MG	N75899 002	JAN 17, 2001	JAN	NEWA

	AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
>A>	AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
>A>	AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
>A>	AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
	AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
	AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA
		FORMOTEROL FUMARATE					
		CAPSULE; INHALATION					
		FORADIL					
	+	NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA
		GABAPENTIN					
		CAPSULE; ORAL					
		NEURONTIN					
		PFIZER	100MG	N20235 001	DEC 30, 1993	MAR	CAHN
			300MG	N20235 002	DEC 30, 1993	MAR	CAHN
	+		400MG	N20235 003	DEC 30, 1993	MAR	CAHN
		GALANTAMINE HYDROBROMIDE					
		TABLET; ORAL					
		REMINYL					
		JANSSEN RES FDN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA
			EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA
	+		EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA
		GEMFIBROZIL					
		TABLET; ORAL					
		GEMFIBROZIL					
	AB	GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995	JAN	CAHN
		GENTAMICIN SULFATE					
		INJECTABLE; INJECTION					
		GENTAMICIN SULFATE					
>D>	AP	GENSIA SICOR PHARMS	EQ 40MG BASE/ML	N63106 002	NOV 21, 1991	APR	DISC
>A>		@	EQ 40MG BASE/ML	N63106 002	NOV 21, 1991	APR	DISC
>D>	AP	STERIS	EQ 10MG BASE/ML	N62318 002	AUG 20, 1981	APR	DISC
>D>	AP		EQ 40MG BASE/ML	N62318 001	JUN 02, 1981	APR	DISC
>A>		@	EQ 10MG BASE/ML	N62318 002	AUG 20, 1981	APR	DISC
>A>		@	EQ 40MG BASE/ML	N62318 001	JUN 02, 1981	APR	DISC
		U-GENCIN					
		@ PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP
		@	EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP
>D>		INJECTABLE; INTRATHECAL					
>D>		GARAMYCIN					
>D>	+	SCHERING	EQ 2MG BASE/ML	N50505 001	OCT 01, 1979	APR	DISC
>A>		@	EQ 2MG BASE/ML	N50505 001	OCT 01, 1979	APR	DISC
		OINTMENT; OPHTHALMIC					
		GENTACIDIN					
	AT	NOVARTIS	EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN
		SOLUTION/DROPS; OPHTHALMIC					
	AT	NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN

GENTAMICIN SULFATE
SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

>D>	AT	ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001	NOV 25, 1985	APR	DISC
>A>		@	EQ 0.3% BASE	N62523 001	NOV 25, 1985	APR	DISC

GLIPIZIDE
TABLET; ORAL
GLIPIZIDE

	AB	GENEVA PHARMS TECH	5MG	N74542 001	JUN 20, 1995	JAN	CAHN
	AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN

GRISEOFULVIN, MICROCRYSTALLINE
SUSPENSION; ORAL
GRIFULVIN V

	+	J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD
		@ JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
GRISACTIN ULTRA

>D>	AB	WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC
>D>	AB		250MG	N62178 002	MAR 13, 1980	APR	DISC
>A>		@	125MG	N62178 001	MAR 13, 1980	APR	DISC
>A>		@	250MG	N62178 002	MAR 13, 1980	APR	DISC

HALOPERIDOL LACTATE
INJECTABLE; INJECTION
HALOPERIDOL LACTATE

	AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	MAR	NEWA

HALOTHANE
LIQUID; INHALATION
HALOTHANE

		@ BH	99.99%	N84977 001	JUL 14, 1976	JAN	DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM PRESERVATIVE FREE

		@ PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	FEB 22, 1980	FEB	WDRP

HYDRALAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDRALAZINE HCL

	AP	AM PHARM PARTNERS	20MG/ML	N40388 001	MAR 13, 2001	MAR	NEWA

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE AND HYDROCHLOROTHIAZIDE-50

		@ WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP

HYDROCORTISONE
CREAM; TOPICAL
HC (HYDROCORTISONE)
@ C AND M PHARMA 0.5% N80482 003 MAR 20, 1973 FEB WDRP
@ 1% N80482 004 MAR 20, 1973 FEB WDRP
HYDROCORTISONE
@ TOPIDERM 1% N89273 001 FEB 17, 1989 FEB WDRP
PROCTOCORT
@ MONARCH PHARMS 1% N83011 001 APR 26, 1973 FEB DISC
LOTION; TOPICAL
BETA-HC
@ BETA DERMAC 1% N89495 001 JAN 25, 1988 FEB WDRP
GLYCORT
@ HERAN 1% N87489 001 OCT 03, 1983 FEB WDRP
OINTMENT; TOPICAL
HC (HYDROCORTISONE)
@ C AND M PHARMA 1% N80481 002 MAR 20, 1973 FEB WDRP
POWDER; FOR RX COMPOUNDING
H-CORT
@ TORCH 100% N87834 001 MAR 29, 1982 FEB WDRP

HYDROCORTISONE ACETATE
CREAM; TOPICAL
MICORT-HC
FERNDALE LABS 2.5% N40396 001 FEB 27, 2001 FEB NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
OINTMENT; TOPICAL
NEO-CORTEF
>D> + PHARMACIA AND UPJOHN 1%;EQ 3.5MG BASE/GM N60751 002 MAY 18, 1965 APR DISC
>A> @ 1%;EQ 3.5MG BASE/GM N60751 002 MAY 18, 1965 APR DISC
SUSPENSION/DROPS; OPHTHALMIC
COR-OTICIN
@ AKORN 1.5%;EQ 3.5MG BASE/ML N60188 001 OCT 26, 1968 FEB WDRP

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OTIC
NEO-OTOSOL-HC
>D> AT ALCON 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N62423 001 AUG 25, 1983 APR DISC
>A> @ 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N62423 001 AUG 25, 1983 APR DISC
SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
>D> AT ALCON UNIVERSAL 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N62488 001 NOV 06, 1985 APR DISC
>A> @ 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML N62488 001 NOV 06, 1985 APR DISC

HYDROXYZINE PAMOATE
CAPSULE; ORAL
HYDROXYZINE PAMOATE

	@ VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

INDAPAMIDE
TABLET; ORAL
INDAPAMIDE

AB	GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
AB		2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA
AN	NOVEX	0.02%	N75441 001	MAR 28, 2001	MAR	NEWA
AN	WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE

AN	MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN

ISOTRETINOIN
CAPSULE; ORAL
ACCUTANE

>D>	HLR	20MG	N18662 004	MAR 28, 1983	APR	CTEC
>A>	+	20MG	N18662 004	MAR 28, 1983	APR	CTEC

KANAMYCIN SULFATE
INJECTABLE; INJECTION
KANAMYCIN SULFATE

>D>	AP	LOCH	EQ 1GM BASE/3ML	N63025 001	JUL 31, 1992	APR	DISC
>A>		@	EQ 1GM BASE/3ML	N63025 001	JUL 31, 1992	APR	DISC

LAMOTRIGINE
TABLET, CHEWABLE; ORAL
LAMICTAL CD

	GLAXO WELLCOME	2MG	N20764 004	SEP 08, 2000	MAR	NEWA

LEUCOVORIN CALCIUM
INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001	JAN	NEWA

LEVOCARNITINE
INJECTABLE; INJECTION
CARNITOR

AP	+	SIGMA TAU	200MG/ML	N20182 001	DEC 16, 1992	MAR	CFTG

LEVOCARNITINE

AP	BEDFORD	200MG/ML	N75567 001	MAR 29, 2001	MAR	NEWA
AP	GENSIA SICOR PHARMS	200MG/ML	N75881 001	MAR 29, 2001	MAR	NEWA

			LIDOCAINE HYDROCHLORIDE					
			INJECTABLE; INJECTION					
			LIDOCATON					
			@ PHARMATON	2%	N84727 001	AUG 17, 1983	FEB	WDRP
			LISINOPRIL					
			TABLET; ORAL					
			ZESTRIL					
>D>	AB	+	ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC
>A>	AB			10MG	N19777 002	MAY 19, 1988	APR	CTEC
			MEPROBAMATE					
			TABLET; ORAL					
			AMOSENE					
			@ FERNDALE LABS	400MG	N84030 001	MAY 10, 1974	FEB	WDRP
			MESALAMINE					
			SUPPOSITORY; RECTAL					
			CANASA					
		+	AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA
			MESNA					
			INJECTABLE; INTRAVENOUS					
>A>			MESNA					
>A>	AP		AM PHARM PARTNERS	100MG/ML	N75811 001	APR 26, 2001	APR	NEWA
>A>	AP		GENSIA SICOR PHARMS	100MG/ML	N75764 001	APR 27, 2001	APR	NEWA
>A>			MESNEX					
>A>	AP	+	ASTA	100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG
>D>		+		100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG
			METAPROTERENOL SULFATE					
			SOLUTION; INHALATION					
			METAPROTERENOL SULFATE					
	AN		NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA
	AN			0.6%	N75403 001	FEB 28, 2001	FEB	NEWA
			METHIMAZOLE					
			TABLET; ORAL					
			METHIMAZOLE					
	AB		EON	5MG	N40411 001	MAR 27, 2001	MAR	NEWA
	AB			10MG	N40411 002	MAR 27, 2001	MAR	NEWA
			METHOTREXATE SODIUM					
			TABLET; ORAL					
			TREXALL					
			BARR	EQ 5MG BASE	N40385 001	MAR 21, 2001	MAR	NEWA
				EQ 7.5MG BASE	N40385 002	MAR 21, 2001	MAR	NEWA
				EQ 10MG BASE	N40385 003	MAR 21, 2001	MAR	NEWA
		+		EQ 15MG BASE	N40385 004	MAR 21, 2001	MAR	NEWA

METHYLPHENIDATE HYDROCHLORIDE

>A>		CAPSULE, EXTENDED RELEASE; ORAL					
>A>		METADATE CD					
>A>	+	CELLTECH PHARMS	20MG	N21259 001	APR 03, 2001	APR	NEWA
		TABLET; ORAL					
>A>		METHYLPHENIDATE HCL					
	AB	ABLE	5MG	N40404 001	MAR 29, 2001	MAR	NEWA
	AB		10MG	N40404 002	MAR 29, 2001	MAR	NEWA
	AB		20MG	N40404 003	MAR 29, 2001	MAR	NEWA
		TABLET, EXTENDED RELEASE; ORAL					
>A>		METADATE ER					
>A>	AB	CELLTECH PHARMS	10MG	N40306 001	OCT 20, 1999	APR	CTEC
>D>	AB +	MEDEVA	10MG	N40306 001	OCT 20, 1999	APR	CTEC
>A>		METHYLPHENIDATE HCL					
	AB	DANBURY PHARMA	20MG	N40410 001	FEB 09, 2001	FEB	NEWA

METHYLTESTOSTERONE

		TABLET; BUCCAL					
		ORETON					
		@ SCHERING	10MG	N80281 001	AUG 03, 1979	FEB	DISC

METOCLOPRAMIDE HYDROCHLORIDE

		SOLUTION; INJECTION					
		METOCLOPRAMIDE					
	AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA
		TABLET; ORAL					
		METOCLOPRAMIDE HCL					
	AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN
	AB		EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN

METOPROLOL SUCCINATE

		TABLET, EXTENDED RELEASE; ORAL					
		TOPROL-XL					
	+	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA

METRONIDAZOLE

		TABLET; ORAL					
		PROTOSTAT					
		@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC
		@	500MG	N18871 002	MAR 02, 1983	MAR	DISC

MINOCYCLINE HYDROCHLORIDE

		CAPSULE; ORAL					
		MINOCIN					
	AB	LEDERLE	EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	NEWA
	AB +		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CRLD
		MINOCYCLINE HCL					
	AB	DANBURY PHARMA	EQ 100MG BASE	N63065 001	DEC 30, 1991	MAR	CRLD
>A>	AB	IMPAX LABS	EQ 75MG BASE	N65005 003	APR 18, 2001	APR	NEWA
		POWDER, EXTENDED RELEASE; DENTAL					
		ARESTIN					
	+	ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA

MIRTAZAPINE
TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB
\+ ORGANON INC

	15MG	N21208 001	JAN 12, 2001	JAN	NEWA
	30MG	N21208 002	JAN 12, 2001	JAN	NEWA
	45MG	N21208 003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE
TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE
AB WATSON LABS

	100MG	N75656 001	JAN 30, 2001	JAN	NEWA

NADOLOL
TABLET; ORAL
NADOLOL
AB GENEVA PHARMS TECH

AB	20MG				
AB	40MG	N74501 001	NOV 09, 1995	JAN	CAHN
AB	80MG	N74501 002	NOV 09, 1995	JAN	CAHN
		N74501 003	NOV 09, 1995	JAN	CAHN

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE
@ WYETH AYERST

@	0.02MG/ML	N70188 001	SEP 24, 1986	JAN	DISC
@	0.02MG/ML	N70189 001	SEP 24, 1986	JAN	DISC
@	0.4MG/ML	N70190 001	SEP 24, 1986	JAN	DISC
@	0.4MG/ML	N70191 001	SEP 24, 1986	JAN	DISC

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
VASOCON
AT NOVARTIS

	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN

NAPROXEN
TABLET, EXTENDED RELEASE; ORAL
NAPROXEN
>A> AB + ALPHAPHARM

>A> AB +	375MG				
	500MG	N75390 001	APR 19, 2001	APR	NEWA
		N75390 002	APR 19, 2001	APR	NEWA

NAPROXEN SODIUM
TABLET; ORAL
NAPROXEN SODIUM
AB GENEVA PHARMS TECH

AB	EQ 250MG BASE				
	EQ 500MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN
		N74495 002	DEC 05, 1994	JAN	CAHN

NEFAZODONE HYDROCHLORIDE
TABLET; ORAL
SERZONE
>D> + BRISTOL MYERS SQUIBB

>A>	50MG				
	50MG	N20152 001	DEC 22, 1994	APR	CTEC
		N20152 001	DEC 22, 1994	APR	CTEC

		NIFEDIPINE					
		CAPSULE; ORAL					
		NIFEDIPINE					
		@ CHASE LABS NJ	10MG	N72409 001	JUL 04, 1990	FEB	WDRP
		@	20MG	N73421 001	JUN 19, 1991	FEB	WDRP
		TABLET, EXTENDED RELEASE; ORAL					
		ADALAT CC					
>D>	AB +	BAYER	30MG	N20198 001	APR 21, 1993	APR	CTEC
>A>	AB		30MG	N20198 001	APR 21, 1993	APR	CTEC
		NIFEDIPINE					
	AB2	BIOVAIL	30MG	N75289 002	FEB 06, 2001	FEB	NEWA
		PROCARDIA XL					
	AB2 +	PFIZER	30MG	N19684 001	SEP 06, 1989	FEB	CTEC
		NITROFURAZONE					
		POWDER; TOPICAL					
		FURACIN					
		@ ROBERTS LABS	0.2%	N83791 001	OCT 17, 1975	FEB	WDRP
		NITROGLYCERIN					
		AEROSOL; SUBLINGUAL					
		NITROLINGUAL					
>D>	+	POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR	DISC
>A>		@	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR	DISC
		NYSTATIN					
		TABLET; VAGINAL					
		KOROSTATIN					
		@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP
		OXACILLIN SODIUM					
		INJECTABLE; INJECTION					
		BACTOCILL					
		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC
		@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC
		OXACILLIN SODIUM					
	AP +	APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD
	AP +		EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD
		OXAPROZIN					
		TABLET; ORAL					
		DAYPRO					
	AB +	SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG
		OXAPROZIN					
	AB	DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA
	AB	EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA
>A>	AB	GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA
	AB	GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA
>A>	AB	INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA
	AB	WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA

OXYTETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
OXYTETRACYCLINE HCL

	@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
	@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP

PACLITAXEL
INJECTABLE; INJECTION
PACLITAXEL

AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION

>A>	AREDIA					
>A> AP +	NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG
>A> AP +		90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG
>D> +		30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG
>D> +		90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG
>A>	PAMIDRONATE DISODIUM					
>A> AP	BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA
>A> AP		90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA

PANTOPRAZOLE SODIUM
INJECTABLE; IV (INFUSION)
PROTONIX IV

+	WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA

PEMOLINE
TABLET; ORAL
PEMOLINE

AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA
AB		37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA
AB		75MG	N75726 001	MAR 30, 2001	MAR	NEWA

PENICILLIN G SODIUM
INJECTABLE; IM-IV
PENICILLIN G SODIUM

+	BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	FEB 26, 2001	FEB	NEWA
	@ MARSAM	5,000,000 UNITS/VIAL	N63014 001	SEP 13, 1988	FEB	DISC

PERPHENAZINE
CONCENTRATE; ORAL
TRILAFON

	@ SCHERING	16MG/5ML	N11557 001	DEC 12, 1958	MAR	DISC

PHENYTOIN
SUSPENSION; ORAL
PHENYTOIN

AB	UDL	125MG/5ML	N40342 001	JAN 31, 2001	JAN	NEWA

			POTASSIUM CHLORIDE						
			TABLET, EXTENDED RELEASE; ORAL						
			K-DUR 10						
>D>	AB	+	KEY PHARMS	10MEQ	N19439	002	JUN 13, 1986	APR	CTEC
>A>	AB			10MEQ	N19439	002	JUN 13, 1986	APR	CTEC
			PREDNICARBATE						
			OINTMENT; TOPICAL						
			DERMATOP						
		+	AVENTIS PHARMS	0.1%	N19568	001	SEP 23, 1991	MAR	CMFD
			PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM						
			OINTMENT; OPHTHALMIC						
			VASOCIDIN						
	AT		NOVARTIS	0.5%;10%	N88791	001	OCT 05, 1984	FEB	CAHN
			SUSPENSION/DROPS; OPHTHALMIC						
			METIMYD						
		+	SCHERING	0.5%;10%	N10210	001	FEB 24, 1956	FEB	CTEC
			PREDAMIDE						
		@	AKORN	0.5%;10%	N88059	001	JUL 29, 1983	FEB	WDRP
			SULPHRIN						
		@	BAUSCH AND LOMB	0.5%;10%	N88089	001	DEC 28, 1982	FEB	WDRP
			PREDNISOLONE SODIUM PHOSPHATE						
			SOLUTION/DROPS; OPHTHALMIC						
			INFLAMASE FORTE						
	AT	+	NOVARTIS	EQ 0.9% PHOSPHATE	N80751	002	DEC 19, 1973	FEB	CAHN
			INFLAMASE MILD						
	AT	+	NOVARTIS	EQ 0.11% PHOSPHATE	N80751	001	DEC 19, 1973	FEB	CAHN
			PREDNISOLONE SODIUM PHOSPHATE						
		@	AKORN	EQ 0.11% PHOSPHATE	N83358	001	AUG 21, 1974	FEB	WDRP
		@		EQ 0.9% PHOSPHATE	N83358	002	AUG 21, 1974	FEB	WDRP
			PROCHLORPERAZINE MALEATE						
			TABLET; ORAL						
			PROCHLORPERAZINE MALEATE						
	AB		GENEVA PHARMS TECH	EQ 5MG BASE	N40101	001	JUL 19, 1996	JAN	CAHN
	AB			EQ 10MG BASE	N40101	002	JUL 19, 1996	JAN	CAHN
	AB			EQ 25MG BASE	N40101	003	JUL 19, 1996	JAN	CAHN
			PROGESTERONE						
			INJECTABLE; INJECTION						
>A>			PROGESTERONE						
>A>	AO		AM PHARM PARTNERS	50MG/ML	N75906	001	APR 25, 2001	APR	NEWA
>D>	AO	+	STERIS	50MG/ML	N17362	002	MAY 08, 1978	APR	CFTG
>A>	AO	+		50MG/ML	N17362	002	MAY 08, 1978	APR	CFTG
			PROTRIPTYLINE HYDROCHLORIDE						
			TABLET; ORAL						
			PROTRIPTYLINE HCL						
	AB		ODYSSEY PHARMS	5MG	N73644	001	AUG 24, 1995	JAN	CAHN
	AB			10MG	N73645	001	AUG 24, 1995	JAN	CAHN

PROTRIPTYLINE HYDROCHLORIDE
TABLET; ORAL
VIVACTIL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	MAR	CTNA		
AB +		10MG	N73645 001	AUG 24, 1995	MAR	CTNA		>A>
@	SIDMAK LABS	5MG	N16012 001	SEP 27, 1967	MAR	DISC		>A>
@		10MG	N16012 002	SEP 27, 1967	MAR	DISC		>A>
								>A>

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SYRUP; ORAL
TRILITRON

@	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474 001	FEB 12, 1985	FEB	WDRP		

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE

BX +	BERLEX LABS	324MG	N16647 001	DEC 08, 1969	MAR	CTEC		

QUINIDINE GLUCONATE

BX	DANBURY PHARMA	324MG	N87810 001	SEP 29, 1982	MAR	CTEC		
@	GENEVA PHARMS	324MG	N89894 001	DEC 15, 1988	MAR	DISC		
BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAR	CTEC		

QUINIDINE SULFATE
TABLET; ORAL
QUINIDINE SULFATE

@	IMPAX LABS	200MG	N83347 001	DEC 08, 1976	FEB	DISC		

RIFAMPIN
CAPSULE; ORAL
RIFAMPIN

AB	VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA		
AB		300MG	N65028 002	MAR 14, 2001	MAR	NEWA		

RISPERIDONE
TABLET; ORAL
RISPERDAL

								>D>
>A>	JANSSEN	0.5MG						>A>
>A> +		1MG	N20272 007	JAN 27, 1999	APR	CRLD		
>A>		4MG	N20272 001	DEC 29, 1993	APR	CRLD		
>D> +	JANSSEN RES FDN	0.5MG	N20272 004	DEC 29, 1993	APR	CRLD		
>D>		1MG	N20272 007	JAN 27, 1999	APR	CRLD		>A>
>D> +		4MG	N20272 001	DEC 29, 1993	APR	CRLD		>A>
			N20272 004	DEC 29, 1993	APR	CRLD		>A>
								>A>

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM

@	ICN	100MG	N85477 001	DEC 10, 1981	FEB	WDRP		

SIMVASTATIN
TABLET; ORAL
ZOCOR

>D> +	MERCK	5MG						>A>
>A>		5MG	N19766 001	DEC 23, 1991	APR	CTEC		>A>
			N19766 001	DEC 23, 1991	APR	CTEC		>D>

		SOTALOL HYDROCHLORIDE						
		TABLET; ORAL						
		SORINE						
>A>	AB	UPSHER SMITH	80MG	N75500 001	APR 27, 2001	APR	NEWA
>A>	AB		120MG	N75500 004	APR 27, 2001	APR	NEWA
>A>	AB		160MG	N75500 002	APR 27, 2001	APR	NEWA
>A>	AB		240MG	N75500 003	APR 27, 2001	APR	NEWA
		SULFACETAMIDE SODIUM						
		SOLUTION/DROPS; OPHTHALMIC						
		SULF-10						
		@ NOVARTIS	10%	N80025 001	JUN 03, 1971	FEB	CAHN
		SULF-15						
	AT	NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN
		SULTEN-10						
		@ BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP
		SULFAMETHOXAZOLE; TRIMETHOPRIM						
		SUSPENSION; ORAL						
		TRIMETH/SULFA						
		@ NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP
		SULFANILAMIDE						
		CREAM; VAGINAL						
		AVC						
	AT +	NOVAVAX	15%	N06530 003	JAN 27, 1987	JAN	CAHN
		SUPPOSITORY; VAGINAL						
	+	NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	JAN	CAHN
		TECHNETIUM TC-99M APCITIDE						
		INJECTABLE; INJECTION						
		ACUTECT						
>D>		DIATIDE	N/A	N20887 001	SEP 14, 1998	APR	CAHN
>A>		DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998	APR	CAHN
		TERAZOSIN HYDROCHLORIDE						
		CAPSULE; ORAL						
		TERAZOSIN HCL						
>A>	AB	TORPHARM	EQ 1MG BASE	N75498 001	APR 12, 2001	APR	NEWA
>A>	AB		EQ 2MG BASE	N75498 002	APR 12, 2001	APR	NEWA
>A>	AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA
>A>	AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
	AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
	AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
	AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA
		THIOTEPA						
		INJECTABLE; INJECTION						
>A>		THIOPLEX						
>A>	AP +	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG
>D>	+		15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG

THIOTEPA

INJECTABLE; INJECTION

>A>		THIOTEPA					
>A>	AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
>A>	AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
>A>	+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA
>D>	+	IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC
>A>	@		15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC

THYROGLOBULIN

TABLET; ORAL

THYROGLOBULIN

	@	IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC

TOPIRAMATE

TABLET; ORAL

TOPAMAX

	+	JOHNSON RW	25MG	N20505 004	DEC 24, 1996	MAR	CRLD
			200MG	N20505 002	DEC 24, 1996	MAR	CRLD

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

	+	ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001	MAR	NEWA

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

	@	IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	@	TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
	@		0.1%	N89275 001	FEB 21, 1989	FEB	WDRP
	@		0.5%	N89276 001	FEB 21, 1989	FEB	WDRP

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLOREX

	@	LANNETT	4MG	N85630 001	MAY 16, 1977	FEB	WDRP

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HCL

AB		GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001	OCT 25, 1996	JAN	CAHN
AB			EQ 2MG BASE	N40153 002	OCT 25, 1996	JAN	CAHN
AB			EQ 5MG BASE	N40153 003	OCT 25, 1996	JAN	CAHN
AB			EQ 10MG BASE	N40153 004	OCT 25, 1996	JAN	CAHN

VALGANCICLOVIR HYDROCHLORIDE
TABLET; ORAL
VALCYTE

+ SYNTEX (USA) INC LLC	EQ 450MG BASE	N21304 001	MAR 29, 2001	MAR	NEWA

VITAMIN A PALMITATE
CAPSULE; ORAL
VITAMIN A

@ WEST WARD	EQ 50,000 UNITS BASE	N80967 001	MAY 04, 1973	FEB	WDRP

ZIPRASIDONE HYDROCHLORIDE
CAPSULE; ORAL
GEODON

PFIZER	20MG	N20825 001	FEB 05, 2001	FEB	NEWA
	40MG	N20825 002	FEB 05, 2001	FEB	NEWA
	60MG	N20825 003	FEB 05, 2001	FEB	NEWA
+	80MG	N20825 004	FEB 05, 2001	FEB	NEWA

ZOLMITRIPTAN
TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT

ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA

ACETAMINOPHEN
SUPPOSITORY; RECTAL

	ACETAMINOPHEN					
	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
+		650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL

	TAVIST ALLERGY/SINUS/HEADACHE					
+	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL

	TAVIST-D					
@	NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
@		1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL

>A>	IBUPROHM COLD AND SINUS					
>A>	OHM LABS	200MG;30MG	N74567 001	APR 17, 2001	APR	NEWA

MICONAZOLE NITRATE
CREAM; TOPICAL

	MONISTAT 3 COMBINATION PACK					
+	PERSONAL PRODS	2%;4%	N21261 001	FEB 02, 2001	FEB	NEWA

CREAM; VAGINAL

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL '01

NO APRIL 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
April 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=
Busulfan TN=Spartajet-Busulfan	Intrathecal therapy for neoplastic meningitis	The Brain Tumor Center at Duke Duke University Medical Center Room 047, Baker House, South Durham NC 27710 DD= 3/5/01 MA=
Coenzyme Q10 TN=	For the treatrment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520 DD= 3/5/01 MA=
docosahexanoic acid-paclitaxel TN=Taxoprexin	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377 DD= 3/5/01 MA=
h5G1.1mAb TN=	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 3/5/01 MA=

Orphan Products Designations and Approvals List
April 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Hsp E7 TN=	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655 DD= 3/19/01 MA=
Imatinib TN=Glivec	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA=
Interferon-alfa-1b TN=	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery 9500 Euclid Avenue Clevland OH 44195 DD= 4/17/01 MA=
Medroxyprogesterone acetate TN=Hematrol	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University and 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=

Orphan Products Designations and Approvals List
April 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=
NZ-1002 TN=	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 4/11/01 MA=
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt TN=	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703 DD= 3/7/01 MA=
Perflubron TN=LiquiVent	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road San Diego CA 92191 DD= 4/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822 DD= 2/21/01 MA=

Orphan Products Designations and Approvals List
April 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc. 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=
Synthetic Human Parathyroid Hormone 1-34 TN=	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 3/22/01 MA=
Vasoactive intestinal peptide TN=	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Health Sciences Center T17, 040 Stony Brook NY 11794-8172 DD= 3/9/01 MA=
Virulizin TN= Virulizin	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
	021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
>ADD>	020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
>ADD>	020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA				I-235	SEP 23, 2001
						I-262	JUN 02, 2002
>ADD>	021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
	020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	021001 001	ALMOTRIPTAN MALATE;AXERT				NCE	MAY 07, 2006
	021001 002	ALMOTRIPTAN MALATE;AXERT				NCE	MAY 07, 2006
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013		NC	JUL 14, 2003
			5053432	OCT 01, 2008			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
	019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
>ADD>	021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015			
>ADD>			5962731	OCT 05, 2016			
>ADD>			5466861	NOV 14, 2012			
	021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P				NP	MAY 16, 2004
	074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
	075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
	018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013			
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			
019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
021005 001	DICLOFENAC SODIUM;SOLARAZE				NP	OCT 16, 2003
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
		5254539	AUG 29, 2006	U-248		
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
>ADD>	020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
>ADD>	020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
>ADD>	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4508905	FEB 20, 2001		NP	FEB 20, 2004
			4255431	APR 05, 2001	U-373		
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
>ADD>	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4508905	FEB 20, 2001		NP	FEB 20, 2004
			4255431	APR 05, 2001	U-373		
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
	020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
	020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
	020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
	020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
>ADD>	020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
>ADD>						PED	MAY 09, 2002
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
>ADD>	020985 001	FLUOROURACIL;FLUOROURACIL	4690825	OCT 04, 2005			
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
>ADD>	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
>ADD>			5290815	MAR 01, 2011	U-386		
>ADD>	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
>ADD>			5290815	MAR 01, 2011	U-386		
>ADD>	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
>ADD>			5290815	MAR 01, 2011	U-386		
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
>ADD>	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
	021335 002	IMATINIB MESYLATE;GLEEVEC				NCE	MAY 10, 2006
						ODE	MAY 10, 2008
	021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014			
	020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
>ADD>	018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
>ADD>			4464394*PED	FEB 07, 2002			
>ADD>	018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
>ADD>			4464394*PED	FEB 07, 2002			
>ADD>	018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
>ADD>			4464394*PED	FEB 07, 2002			
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
>ADD>	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			
>ADD>	021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
>ADD>	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
>ADD>	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
	021204 002	NATEGLINIDE;STARLIX	5488150	JAN 30, 2013			
			RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
>ADD>	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
>ADD>			5633008	JUN 14, 2008	U-389		
>ADD>	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
>ADD>			6165497	JUN 14, 2008	U-388		
>ADD>	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
>ADD>			6165497	JUN 14, 2008	U-388		
	075269 001	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
			5605897	FEB 25, 2014	U-176		
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
	019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			4508905	APR 02, 2002			
	019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014			
			5629305*PED	AUG 04, 2014	U-166		
			6147103*PED	APR 09, 2019	U-188		
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
			6147103	OCT 09, 2018		PED	DEC 29, 2001
			6166213	NOV 10, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
			5866601	FEB 02, 2016		NDF	DEC 14, 2003
			5952375	FEB 02, 2016		NCE	OCT 27, 2004
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
	020262 001	PACLITAXEL;TAXOL	6150398	MAY 08, 2011	U-380		
>ADD>	020987 001	PANTOPRAZOLE SODIUM;PROTONIX				I-330	JUN 12, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2005		NDF	MAR 22, 2004
						NCE	FEB 02, 2005
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						I-326	APR 13, 2004
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL					
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			5789449	JAN 06, 2009	U-286		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
			6172233	JAN 15, 2018			
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		I-322	FEB 20, 2004
	019627 002	PROPOFOL;DIPRIVAN	5045552	SEP 03, 2008	U-385		
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U-385		
			4418068	APR 03, 2002			
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	6172046	SEP 21, 2017	U-377 PED		JUN 09, 2002
	020903 001	RIBAVIRIN;REBETOL	5767097*PED	JUL 23, 2016	U-235 PED		DEC 03, 2001
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
			6063772*PED	JUL 23, 2017	U-375		
			6172046*PED	MAR 21, 2018	U-377		
			6232333	NOV 07, 2017			
>ADD>	020945 001	RITONAVIR;NORVIR	5474995	JUN 24, 2013	U-266		
>ADD>	021042 001	ROFECOXIB;VIOXX	5691374	NOV 25, 2017			
>ADD>			6239173	JUN 24, 2013			
>ADD>			5474995	JUN 24, 2013	U-266		
>ADD>	021042 002	ROFECOXIB;VIOXX	5691374	NOV 25, 2017			
>ADD>			6239173	JUN 24, 2013			
>ADD>			6239173	JUN 24, 2013			
>ADD>	021042 003	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
>ADD>			5691374	NOV 25, 2017			
>ADD>			6239173	JUN 24, 2013			
>ADD>	021052 001	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
>ADD>	021052 002	ROFECOXIB;VIOXX				D-65	FEB 16, 2004
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA					
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
						NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF					
			6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
	021257 001	TRAVOPROST;TRAVATAN	5631287	DEC 22, 2014	U-382		
			5849792	DEC 22, 2014	U-383		
			5889052	AUG 03, 2013	U-383		
			6235781	JUN 15, 2019	U-382		
			5955109	SEP 21, 2016	U-134		
			6143329	JUL 03, 2016			
>ADD>	020475 001	TRETINOIN;RETIN-A MICRO	6187341	JAN 20, 2019			
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6187341	JAN 20, 2019			
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN				I-325	MAY 02, 2004
	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE				I-325	MAY 02, 2004
	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-325	MAY 02, 2004
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-328	SEP 17, 2002
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-328	SEP 17, 2002
	020547 001	ZAFIRLUKAST;ACCOLATE				M-8	FEB 22, 2004
	020547 003	ZAFIRLUKAST;ACCOLATE				M-8	FEB 22, 2004
	020859 001	ZALEPLON;SONATA				NCE	FEB 05, 2006
	020859 002	ZALEPLON;SONATA	4831031	MAR 02, 2007			
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	5312925	SEP 01, 2012			
			4831031	MAR 02, 2007		NCE	FEB 05, 2006
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	5312925	SEP 01, 2012			
			4831031	MAR 02, 2007		NCE	FEB 05, 2006
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	5312925	SEP 01, 2012			
			4831031	MAR 02, 2007		NCE	FEB 05, 2006
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	5312925	SEP 01, 2012			
						NDF	FEB 13, 2004
	021231 001	ZOLMITRIPTAN;ZOMIG-ZMT					

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS

D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI

NEW INDICATION

I-321 JUVENILE RHEUMATOID ARTHRITIS

I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS

I-323 COLORECTAL CANCER

I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS

I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION

I-326 GENERALIZED ANXIETY DISORDER

I-327 SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER

I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE

I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

I-330 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD

MISCELLANEOUS EXCLUSIVITY CODES

M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN

M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION

M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

*U.S. Government Printing Office: 2001 — 472-432/21011